Director, Quantitative Systems Pharmacology

Develop, implement, and apply QSP models to understand diseases, their pathways, and their progressions. Evaluate DHBL drug candidates and treatment modalities to predict their effects and optimize therapeutic strategies (e.g., the selection of target tumor types and populations), and to support clinical introduction including first-in-human dose selection.

Use and improve existing Neurology QSP Platforms to gain insights into the causal relationships between biological and drug-level responses, enhancing the understanding of drug-target interactions and disease mechanisms. Develop new QSP models and platforms as they are needed.

Lead DHBL preclinical and early clinical QSP development strategy to support optimal dose selection with simulations based on mechanistic understanding to assess efficacy and safety.

Advocate for model-informed drug discovery and development (MIDD) approaches. Provide scientific leadership, present research at scientific conferences, and integrate MIDD strategies into Eisai’s R&D programs to improve efficiency and decision-making.

Foster collaboration across functional groups and promote the development of new modeling tools and methods. Advance the adoption of QSP capabilities to improve the predictive power of these tools to support the design and optimization of drug combinations.

Manage the expectations/timelines of assigned M&S work for the relevant project teams.

Use mathematical, computational, and statistical tools to analyze and interpret large, complex data sets to gain insights into the causal relationships between drug-target interactions and disease mechanisms.

Provide scientific/strategic expertise across multiple therapeutic areas to support decision-making in the conversion of discovery to clinical through the design, development, and execution of quantitative mechanistic models to support the translational process.